{"data":{"ModuleTitle":{"label":"Module Title","value":"Company Description"},"CompanyName":{"label":"Company Name","value":"Galecto, Inc."},"Symbol":{"label":"Symbol","value":"GLTO"},"Address":{"label":"Address","value":"OLE MAALOES VEJ 3, COPENHAGEN, DK-2200, Denmark"},"Phone":{"label":"Phone","value":"+45 70705210"},"Industry":{"label":"Industry","value":"Biotechnology: Pharmaceutical Preparations"},"Sector":{"label":"Sector","value":"Health Care"},"Region":{"label":"Region","value":"Europe"},"CompanyDescription":{"label":"Company Description","value":"Galecto Inc is a clinical-stage biotechnology company developing therapeutics designed to target the biological processes that lie at the heart of fibrosis and impact a broad range of fibrotic and related diseases, including cancer. Its initial focus is on the development of small-molecule inhibitors of galectin-3 and lysyl oxidase-like 2, or LOXL2. Its product candidate GB0139 is for the treatment of severe fibrotic lung diseases such as idiopathic pulmonary fibrosis, or IPF, a life-threatening progressive fibrotic disease of the lung. Its product GB1211, a selective oral galectin-3 inhibitor for the treatment of fibrosis related to non-alcoholic steatohepatitis, or NASH, and GB2064, a selective oral inhibitor of LOXL2 that it initially plans to develop for the treatment of myelofibrosis."},"CompanyUrl":{"label":"Company Url","value":"https://www.galecto.com"},"KeyExecutives":{"label":"Key Executives","value":[{"name":"Anders H. Pedersen","title":"Chief Operating Officer"},{"name":"Hans Thalsg√•rd Schambye","title":"President, CEO, Chief Medical Officer & Director"}]}},"message":null,"status":{"rCode":200,"bCodeMessage":null,"developerMessage":null}}